Results 51 to 60 of about 1,663 (174)

374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Howard Streicher, Michael Manos, Philippe Bedard, Osama Rahma, Andrew Brohl, Kevin Tyan, Scott Rodig, Daniel Renouf, Emma Hathaway, Rachel Cunningham   +9 more
doaj   +2 more sources

Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept [PDF]

Cornea, 2017
Purpose: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in ...
Mansour, Ahmad Mohammed Farid Mahmoud
core   +3 more sources

A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. [PDF]

Pancreas, 2019
Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC.   +7 more
europepmc   +3 more sources

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer [PDF]

British Journal of Cancer, 2013
H. Chen, Manuel Modiano, Joel W. Neal, Julie R. Brahmer, James R. Rigas, Robert M. Jotte, Natasha B. Leighl, Jonathan W. Riess, Calvin J. Kuo, L. Liu, Bo Gao, A. Thomas DiCioccio, Alex A. Adjei, Heather A. Wakelee   +13 more
exaly   +2 more sources

Intravitreal ziv-aflibercept for myopic macular neovascularization after pars plana vitrectomy and silicone oil tamponade: a case report. [PDF]

Ann Med Surg (Lond)
Abu Ghedda S, Aljundi R, Baba M, Marashi A.   +3 more
europepmc   +2 more sources

Treatment outcomes of ziv‐aflibercept for treatment‐naïve polypoidal choroidal vasculopathy [PDF]

Acta Ophthalmologica, 2017
Errol W. Chan, Mohab Eldeeb, Vishal Govindhari, Chintan Sarvaiya, Alay Banker, Ahmad M. Mansour, Jay Chhablani   +6 more
openalex   +3 more sources

Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration [PDF]

British Journal of Ophthalmology, 2016
In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in wet age-related macular degeneration (AMD) treated with intravitreal ziv-aflibercept.Prospectively, consecutive patients with wet AMD underwent ziv-aflibercept ...
Ahmad M. Mansour, Jay Chhablani, Rafic Antonios, Rohit Yogi, Muhammad H. Younis, Rola Dakroub, Hasan Chahine   +6 more
openalex   +3 more sources

The use of aflibercept (VEGF trap) in mitigating sulfur mustard-induced corneal neovascularization in a rabbit model

Toxicology Reports, 2023
Sulfur mustard (SM)-induced ocular injury is characterized by an acute inflammatory response that may become chronic or enter a latent phase with delayed pathology.
Ariel Gore, Tamar Kadar, Maayan Cohen, Hila Gutman, Rellie Gez, Shlomit Dachir, Vered Horwitz   +6 more
doaj   +1 more source

Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient

Thoracic Cancer, Volume 14, Issue 8, Page 779-782, March 2023., 2023
Small cell lung cancer patients presenting with metastasis of the iris are rare. Here, we report an extensive stage small cell lung cancer patient who presented with iris metastasis in the right eye and metastasis in the left adrenal gland as disease progression to first‐line chemotherapy plus atezolizumab.
Zhe Huang, Yongchang Zhang
wiley   +1 more source

The Inflation Reduction Act: A boon for the generic and biosimilar industry

Journal of Clinical Pharmacy and Therapeutics, Volume 47, Issue 11, Page 1738-1751, November 2022., 2022
The Inflation Reduction Act gives a significant boost to generics and biosimilars!Soon lowered out‐of‐pocket costBiosimilars promoted and adopted Abstract What is Known and Objective After more than a year of negotiation, a $740 billion climate and health care bill known as The Inflation Reduction Act (IRA) became law on 16 August 2022.
Sarfaraz K. Niazi
wiley   +1 more source